NEOSE DISCLOSES PROTEINS UNDER LICENSE AGREEMENTS WITH NOVO NORDISK

A A

Neose Technologies, Inc. today identified Factors VIIa, VIII and IX as the three proteins that are the subject of license agreements it entered into with Novo Nordisk A/S in November 2003. "We continue to be pleased with the progress of our collaboration with Novo Nordisk to develop long-acting, GlycoPEGylated versions of these proteins. We are excited about the benefits our GlycoPEGylation technology may provide to Novo in broadening their haemostasis product portfolio," said George J. Vergis, Ph.D., Neose president and chief executive officer.
Business Wire